Nuwellis Taps New CFO to Steer Growth Amid Financial Headwinds

MINNEAPOLIS, MN – January 30, 2026 – Nuwellis, Inc. (Nasdaq: NUWE), a medical technology firm focused on precision cardiorenal care, has appointed Carisa Schultz as its new Chief Financial Officer. The move, effective February 2, 2026, installs a leader with extensive public company and healthcare finance experience at a pivotal moment for the company as it navigates significant growth opportunities alongside persistent financial pressures.

Schultz arrives as Nuwellis aims to capitalize on favorable market shifts and expand its product portfolio, making her appointment a critical piece of its strategy to achieve profitability and solidify its market position. The decision signals a clear intent to bolster financial discipline and strategic execution as the company enters what its leadership describes as an “important juncture.”

A Seasoned Financial Hand for a Critical Juncture

Ms. Schultz brings a formidable resume to Nuwellis, honed in the demanding environments of public healthcare companies and Big Four accounting. She most recently served as Vice President of Finance at NeueHealth, the successor to the formerly NYSE-listed Bright Health Group. There, she was instrumental in leading enterprise finance, treasury, and corporate development activities, gaining deep experience in the complex financial machinery of a publicly traded healthcare entity.

Her background also includes foundational early-career experience at Boston Scientific, a giant in the medical technology space, giving her firsthand insight into the specific financial dynamics of the device industry. This blend of med-tech and public market expertise appears tailor-made for Nuwellis’s current needs.

Nuwellis CEO John Erb highlighted this strategic fit in the company’s announcement. “Carisa is a highly accomplished financial leader with strong public-company experience and a deep understanding of healthcare and medical technology,” he stated. “Her expertise and disciplined approach will be instrumental as we continue to execute our strategy and advance our cardiorenal platform.”

Schultz herself acknowledged the timing of her move, expressing enthusiasm to guide the company through its next phase. “I’m excited to join Nuwellis at an important juncture in its growth,” said Ms. Schultz. “The company’s focus on precision cardiorenal care represents a meaningful opportunity, and I look forward to working with the leadership team to support long-term value creation.” Her focus on “long-term value creation” underscores the strategic nature of her role, moving beyond day-to-day accounting to help shape the company’s future trajectory.

Navigating a Challenging Financial Landscape

Schultz’s appointment comes as Nuwellis presents a mixed but evolving financial picture. The company has faced significant headwinds, reporting revenue of $2.22 million for the third quarter of 2025, which fell short of analyst estimates. However, this figure also represented a 29% sequential increase from the prior quarter, suggesting some operational momentum driven by increased use of its consumable products.

Profitability remains a primary challenge. The company has a history of net losses, including a reported net loss of $12.6 million in the second quarter of 2025. Gross margins have also been under pressure, impacted by manufacturing utilization and production volumes. For the third quarter of 2025, gross margin was 65.2%, down from 70.0% in the prior-year period.

Despite these hurdles, there are signs of stabilization and a clear focus on shoring up the balance sheet. Nuwellis has remained debt-free and has been active in securing capital to fund its operations and growth initiatives. The company completed a $5.0 million capital raise in mid-2025 and, just a day before the CFO announcement, revealed a new $5 million private placement and warrant inducement transaction. As of its last reporting, the company held approximately $3.1 million in cash.

This financial context makes the role of a CFO particularly crucial. Schultz will be tasked with managing cash burn, optimizing operational spending, and ensuring the newly raised capital is deployed effectively to drive growth. Her experience in treasury and corporate development will be vital as Nuwellis likely continues to engage with capital markets to fuel its expansion.

Strategy, Growth, and a Shifting Market

The strategic importance of Schultz’s role is amplified by several key developments poised to accelerate Nuwellis’s growth. The company’s flagship product, the Aquadex SmartFlow® System, is designed to remove excess fluid from patients suffering from fluid overload, a common and serious condition, particularly in heart failure patients. The system is already clinically proven, and Nuwellis is pushing to establish it as the standard of care.

A major catalyst for this push came from a recent regulatory change. Effective January 1, 2025, the Centers for Medicare & Medicaid Services (CMS) increased its outpatient payment for Aquadex Ultrafiltration Therapy four-fold to $1,639. This dramatic reimbursement hike fundamentally alters the economic proposition for outpatient clinics and is expected to unlock significant market expansion and drive adoption in heart failure treatment centers.

Furthermore, Nuwellis is not standing still on the innovation front. The company recently announced a definitive agreement to acquire Rendiatech, an Israeli company specializing in automated kidney function monitoring technology. This strategic acquisition is a clear step toward building a more comprehensive cardiorenal platform, moving beyond fluid management to include advanced patient monitoring. Integrating Rendiatech and realizing its value will be a key task for the leadership team, with significant financial oversight required from the new CFO.

Schultz’s mandate will be to provide the financial stewardship necessary to capitalize on these opportunities—leveraging the CMS tailwind, integrating the Rendiatech acquisition, and driving penetration in key growth areas like pediatrics and cardiac surgery.

Investor Reaction and Future Outlook

The market’s initial reaction to the executive change has been complex, reflecting the broader uncertainty and high stakes surrounding the company. While Nuwellis stock (NUWE) saw an initial premarket drop following the news, it closed the trading day with an 8.55% gain, suggesting investors may be cautiously optimistic about the strategic implications of the appointment. This follows a period of strong momentum for the stock, which had gained nearly 90% in the week prior.

Analyst sentiment remains divided, with some maintaining a “Buy” rating while others have downgraded to “Neutral” in recent months. The company’s ownership structure is also notable, with very high insider ownership (around 76%) indicating that leadership is heavily invested in its success, though institutional ownership remains relatively low.

The appointment of a CFO with Schultz’s public-company credentials could be a key factor in building broader investor confidence and attracting more institutional capital. Her disciplined approach is precisely what Wall Street looks for in a small-cap med-tech company aiming to transition from a development-stage entity to a commercially successful and profitable enterprise. Ultimately, her success will be measured by her ability to help Nuwellis translate its technological promise and recent strategic wins into sustainable financial performance and shareholder value.